The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market. The company announced the completion of two ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials ... weight loss of 9.7 percent at a 1.25 mg dose (20 weeks), 16.2 percent at 5 mg (28 weeks ...

Novo is studying the pill version of its experimental drug, amycretin, while others including AstraZeneca are also developing oral obesity treatments. Evercore ISI analyst Umer Raffat, who ...